NANOFORM FINLAND OYJ Company release
Person subject to the notification requirement
Position: Other senior manager
Issuer:
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20220412162005_5
____________________________________________
Transaction date: 2022-04-12
Venue not applicable
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 30000 Unit price:
Aggregated transactions
(1): Volume: 30000 Volume weighted average price:
For further information, please contact:
General Counsel
peter.hanninen@nanoform.com
+358 50 353 040
For investor relations queries, please contact:
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---niklas-sandler,c3545439
https://mb.cision.com/Main/18905/3545439/1563601.pdf
(c) 2022 Cision. All rights reserved., source
